ASCO Annual Meeting | Conference

Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL

June 6th 2023

Treatment with lisocabtagene maraleucel elicited encouraging responses regardless of prior progression on BTK inhibition or absence of clinical benefit with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, meeting the primary end point of the phase 1/2 TRANSCEND CLL 004 trial.

mRNA-4157 Plus Pembrolizumab Improves DMFS in High-Risk Melanoma

June 6th 2023

The combination of mRNA-4157 and pembrolizumab reduced the risk of developing distant metastasis or death by approximately 65% compared with pembrolizumab alone as adjuvant therapy in patients with resected melanoma at high risk of recurrence, according to findings from the phase 2 KEYNOTE-942 trial.

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC

June 6th 2023

Combination treatment consisting of datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy generated responses as first- or second-line treatment for patients with advanced or metastatic non–small cell lung cancer.

Sunvozertinib Demonstrates Antitumor Activity and Tolerability in EGFR Exon 20–mutated NSCLC

June 6th 2023

The novel irreversible EGFR exon 20 insertion inhibitor sunvozertinib demonstrated significant clinical activity and similar safety to prior reports in Chinese patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on prior platinum-based chemotherapy, according to results from the phase 2 WO-KONH6 study.

Pembrolizumab Plus Chemo Does Not Significantly Improve Survival in TKI-resistant, EGFR+ NSCLC

June 6th 2023

The addition of pembrolizumab to pemetrexed and platinum-based chemotherapy resulted in a numerical, but not statistically significant, improvement in progression-free survival or overall survival vs chemotherapy plus placebo in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer.

Dr Peters on Vorasidenib in Residual or Recurrent IDH1/2-Mutant Glioma

June 6th 2023

Katherine B. Peters, MD, PhD, discusses findings from the phase 3 INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 glioma harboring an IDH1 or IDH2 mutation and how these results support the addition of vorasidenib to the treatment armamentarium.

Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOC

June 6th 2023

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.

Dr Bose on Spleen and Symptom Benefit With Pacritinib in Myelofibrosis

June 6th 2023

Prithviraj Bose, MD, discusses key data on the ability of pacritinib to reduce splenomegaly and disease symptoms in patients with myelofibrosis across the cytopenic spectrum.

Dr Andre on Survival Results From the SOLSTICE Trial in mCRC

June 6th 2023

Thierry Andre, MD, discusses negative overall survival results and updated safety data from the phase 3 SOLSTICE trial in metastatic colorectal cancer.

Post-hoc Analysis Shows Maintenance Niraparib Provides Additional Antitumor Activity in Advanced Ovarian Cancer

June 6th 2023

The use of maintenance niraparib enhanced antitumor activity and led to a clinically meaningful increase in progression-free survival vs placebo for patients with newly diagnosed advanced ovarian cancer who displayed measurable residual disease after first-line platinum-based chemotherapy, according to findings from a post hoc subgroup analysis of the phase 3 PRIME study.

Niraparib as Second-line Maintenance Demonstrates Real-world OS Benefit in Recurrent Ovarian Cancer

June 6th 2023

Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer.

Eftilagimod Alpha Plus Pembrolizumab Generates Responses, Safety in Metastatic HNSCC

June 6th 2023

The addition of the soluble LAG-3 protein eftilagimod alpha to pembrolizumab produced responses and was well tolerated in patients with metastatic head and neck squamous cell carcinoma.

Extended Lymphadenectomy Does Not Lead to Survival Benefit in MIBC

June 6th 2023

Extended lymphadenectomy at the time of radical cystectomy did not produce a significant improvement in disease-free survival (DFS) or overall survival (OS) vs standard lymphadenectomy for patients with muscle-invasive bladder cancer.

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

June 6th 2023

Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 6th 2023

The addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurrence compared with chemoradiotherapy alone as frontline therapy in patients with locally advanced nasopharyngeal carcinoma, according to findings from the phase 3 CONTINUUM trial.

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

June 6th 2023

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

Long-Term KEYNOTE-426 Data Continue to Support Frontline Pembrolizumab Plus Axitinib as SOC for Advanced ccRCC

June 5th 2023

The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.

Dr Ma on Sintilimab Plus Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

June 5th 2023

Jun Ma, MD, discusses findings from the phase 3 CONTINUUM trial of sintilimab in combination with induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Dr Tawbi on Nivolumab Plus Relatlimab in Metastatic Melanoma

June 5th 2023

Hussein A. Tawbi, MD, PhD, discusses the 2-year findings from the phase 2/3 RELATIVITY-047 trial of nivolumab plus relatlimab in treatment-naïve patients with metastatic or unresectable melanoma.

Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC

June 5th 2023

The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.